An alternative mechanism whereby increased BCAT1 expression can drive disease progression has been described in CML, where net flux in the enzyme-catalyzed reaction is in the opposite direction, resulting in the production of BCAAs from BCKAs. Here, BCAT1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.